Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans

Circulation

Volumn 101, Issue 24, 2000, Pages 2823-2828

  Cadroy, Yves ^a   Bossavy, Jean Pierre ^a,b   Thalamas, Claire ^a   Sagnard, Luc ^c   Sakariassen, Kjell ^d   Boneu, Bernard ^a  

^a CHU PURPAN   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c SANOFI   (France)

^d NONE

Author keywords

Aspirin; Blood flow; Collagen; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTERY WALL; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS;

EID: 0034691260     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.24.2823     Document Type: Article

References (27)

1. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 1998;114: 470S-488S.
2. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med. 1996;334:1084-1089.
3. Karillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the french multicemer registry. Circulation. 1996;94:1519-1527.
4. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-222.
5. Albiero R, Hall P, Itoh A, et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation: comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation. 1997;95:1145-1156.
6. Schühlen H, Hadamitzky M, Walter H, et al. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Shatz stent placement. Circulation. 1997;97: 2015-2021.
7. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98:2126-2132.
8. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998;98: 1597-1603.
9. Leon MB, Bairn DS, Popma JJ, et al. A clinical trial comparing 3 antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-1671.
10. Savi P, Nurden P, Nurden AT, et al. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9:251-255.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
12. Herbert JM, Dol F, Bemat A, et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80:512-518.
13. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation. 1998;98:2461-2469.
14. Sakariassen KS, Joss R, Muggli R, et al. Collagen type III induced ex vivo thrombogenesis in humans: role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis. 1990;10:276-284.
15. Diquélou A, Lemozy S, Dupouy D, et al. Effect of blood flow on thrombin generation is dependent on the nature of thrombogenic surface. Blood. 1994;84:2206-2213.
16. Bossavy JP, Sakariassen KS, Barret A, et al. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost. 1998;79:162-168.
17. Roald HE, Barstad RM, Engen A, et al. HN-11500-A novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost. 1994;71:103-109.
18. Roald HE, Barstad RM, Kierulf P, et al. Clopidogrel-A platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost. 1994;71:655-662.
19. Bossavy JP, Sakariassen KS, Rübsamen K, et al. Comparison of the antithrombotic effect of PEG-Hirudin and heparin in a human ex vivo model of arterial thrombosis. Arterioscler Thromb Vase Biol. 1999;19: 1348-1353.
20. Bossavy JP, Sakariassen KS, Thalamas C, et al. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis: effect of anticoagulation level and combination therapy with aspirin. Arterioscler Thromb Vase Biol. 1999;19: 2269-2275.
21. Bossavy JP, Thalamas C, Sagnard L, et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in man. Blood. 1998;92:1518-1525.
22. Kuzniar J, Splawinska B, Malinga K, et al. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther. 1996;34:357-362.
23. Sakariassen KS, Roald HE, Salatti JA. Ex vivo models for studying thrombosis: special emphasis on shear rate dependent blood-collagen interactions. In: Hwang NHC, Turitto VT, Yen MRT, eds. Advances in Cardiovascular Engineering. New York, NY: Plenum Press; 1992: 151-174.
24. Béguin S, Kumar R. Thrombin, fibrin and platelets: a resonance loop in which von Willebrand factor is a necessary link. Thromb Haemost. 1997;78:590-594.
25. van Zanten GH, de Graaf S, Slootweg PJ, et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest. 1994;93: 615-632.
26. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95: 594-599.
27. Sakariassen KS, Orning L, Slormorken H. Role of ADP and thromboxanes in human thrombus formation in ex vivo models. Platelets. 1997;8:385-390.